Incyte Corporation
A biopharmaceutical company that develops treatments for blood cancers and other cancers (JAKAFI, ICLUSIG), plus creams for skin conditions like vitiligo and eczema (OPZELURA). Founded in 1991 in Palo Alto, it began as a genomics pioneer selling its LifeSeq gene database to researchers before pivoting to making its own drugs. Its name blends "insight" with "cyt," the Greek root for cell — a nod to its genome-sequencing roots.
Granted 180.6K · Bought 4.11M
Granted 303.8K · Sold 187.5K
Granted 327.0K · Sold 56.0K
Granted 161.1K
Granted 120.4K
Granted 98.2K · Sold 28.6K
Granted 210.2K · Sold 143.4K
Granted 106.6K · Sold 60.8K
Granted 85.3K · Sold 10.9K
Sold 5.8K
Granted 39.4K · Sold 3.2K
Granted 98.5K · Sold 63.2K
Granted 41.7K · Sold 3.1K
Granted 24.8K · Sold 15.8K
Granted 128.6K · Sold 112.4K
Granted 50.7K · Sold 58.3K
Granted 8.2K · Sold 8.2K
Granted 60.1K · Sold 28.2K
Granted 26.3K
Granted 33.1K · Sold 15.0K
Granted 26.6K
Granted 28.0K · Sold 17.9K
Granted 17.9K
Granted 13.3K
Granted 20.8K · Sold 20.0K
Granted 11.6K
Granted 15.7K
Granted 12.9K
Granted 6.5K
Granted 9.5K
Granted 9.4K
Granted 9.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 93 transactions | — | 121.83M | 180.6K | 4.11M | — |
| Hoppenot HerveDirector · 18 transactions | -0.9% | 326.8K | 303.8K | — | 187.5K |
| Cagnoni Pablo JPresident, Global Head of R&D · 18 transactions | — | 240.8K | 327.0K | — | 56.0K |
| Meury WilliamChief Executive Officer, Director, President · 2 transactions | — | 161.1K | 161.1K | — | — |
| Stamoulis ChristianaEVP & Chief Financial Officer · 24 transactions | +212.3% | 125.8Kas of Jul 2025 | 120.4K | — | — |
| Swain Paula JEVP, Human Resources · 25 transactions | +78.7% | 106.5Kas of Jul 2025 | 98.2K | — | 28.6K |
| Stein Steven HCMO & Head of Late-Stage Dev. · 37 transactions | -23.3% | 78.3K | 210.2K | — | 143.4K |
| Pasquale Maria EEVP & General Counsel · 24 transactions | +83.3% | 69.7Kas of Jul 2023 | 106.6K | — | 60.8K |
| Issa Mohamed KhairieEVP, Head of US Oncology · 5 transactions | — | 66.1K | 85.3K | — | 10.9K |
| Mayes Patrick AEVP & Chief Scientific Officer · 3 transactions | — | 60.0K | — | — | 5.8K |
| Dhanak DashyantEVP & Chief Scientific Officer · 14 transactions | +84% | 59.0Kas of Jul 2023 | 39.4K | — | 3.2K |
| Iyengar Vijay KEVP, GMAPPS · 35 transactions | +50.1% | 40.5Kas of Jul 2025 | 98.5K | — | 63.2K |
| Heeson LeeEVP, Head of Incyte Intl · 6 transactions | — | 38.0K | 41.7K | — | 3.1K |
| Dickinson Jonathan ElliottEVP, General Manager, Europe · 19 transactions | +34.1% | 36.4Kas of Sep 2024 | 24.8K | — | 15.8K |
| Flannelly Barry PEVP & General Manager US · 40 transactions | -37.1% | 35.1Kas of Jul 2025 | 128.6K | — | 112.4K |
| Morrissey Michael JamesEVP, Head of Tech. Operations · 28 transactions | -25.1% | 34.1K | 50.7K | — | 58.3K |
| Trower PaulPrincipal Accounting Officer · 4 transactions | 0% | 32.3Kas of Jan 2022 | 8.2K | — | 8.2K |
| Denton Sheila A.EVP & General Counsel · 35 transactions | — | 26.6K | 60.1K | — | 28.2K |
| Upadhyay SuketuEVP & Chief Financial Officer · 1 transaction | — | 26.3K | 26.3K | — | — |
| Clancy Paul JDirector · 26 transactions | +247.7% | 25.4K | 33.1K | — | 15.0K |
| Bienaime Jean JacquesDirector · 7 transactions | +125.2% | 24.4K | 26.6K | — | — |
| Tray ThomasPrincipal Accounting Officer · 33 transactions | — | 23.8K | 28.0K | — | 17.9K |
| Harrigan EdmundDirector · 25 transactions | +370.1% | 22.8K | 17.9K | — | — |
| Fouse Jacqualyn ADirector · 11 transactions | +173.3% | 21.0K | 13.3K | — | — |
| Dixon Wendy LDirector · 5 transactions | +4.4% | 17.8Kas of Mar 2022 | 20.8K | — | 20.0K |
| High Katherine ADirector · 5 transactions | +348.1% | 15.0K | 11.6K | — | — |
| Trotta MatteoEVP, GM, Dermatology US · 6 transactions | — | 14.9K | 15.7K | — | — |
| Brawley Otis WDirector · 6 transactions | — | 12.9K | 12.9K | — | — |
| Basi Ramitpal KEVP, Human Resources · 2 transactions | — | 11.0K | 6.5K | — | — |
| Hoffman Richard A.EVP & General Counsel · 1 transaction | — | 9.5K | 9.5K | — | — |
| Gardner David HEVP, Chief Strategy Officer · 1 transaction | — | 9.4K | 9.4K | — | — |
| Schaffert SusanneDirector · 7 transactions | — | 4.9Kas of Jun 2025 | 9.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +3.27M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.